Heim500124 • BOM
Dr Reddy's Laboratories Ltd
1.227,95 ₹
5. feb., 16:01:27 GMT+5:30 · INR · BOM · Lagalegir fyrirvarar
HlutabréfSkráð hlutabréf í INHöfuðstöðvar: IN
Við síðustu lokun
1.219,65 ₹
Dagbil
1.216,20 ₹ - 1.233,15 ₹
Árabil
1.120,01 ₹ - 1.420,20 ₹
Markaðsvirði
1,02 bn INR
Meðalmagn
86,11 þ.
V/H-hlutf.
19,06
A/V-hlutfall
0,65%
Aðalkauphöll
NSE
CDP-loftslagseinkunn
A-
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(INR)des. 2024Breyting á/á
Tekjur
83,59 ma.15,85%
Rekstrarkostnaður
30,34 ma.19,95%
Nettótekjur
14,13 ma.2,49%
Hagnaðarhlutfall
16,91-11,51%
Hagnaður á hvern hlut
16,941,81%
EBITDA
23,43 ma.13,31%
Virkt skatthlutfall
25,10%
Heildareignir
Heildarskuldir
(INR)des. 2024Breyting á/á
Reiðufé og skammtímafjárfestingar
59,92 ma.-17,41%
Heildareignir
481,06 ma.29,02%
Heildarskuldir
159,49 ma.51,91%
Eigið fé alls
321,56 ma.
Útistandandi hlutabréf
833,12 m.
Eiginfjárgengi
3,20
Arðsemi eigna
9,88%
Ávöxtun eigin fjár
12,81%
Breyting á handbæru fé
(INR)des. 2024Breyting á/á
Nettótekjur
14,13 ma.2,49%
Handbært fé frá rekstri
6,62 ma.39,75%
Reiðufé frá fjárfestingum
-5,46 ma.66,27%
Reiðufé frá fjármögnun
590,00 m.-88,83%
Breyting á handbæru fé
1,75 ma.129,12%
Frjálst peningaflæði
-382,75 m.90,46%
Um
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
Framkvæmdastjóri
Stofnsett
1984
Vefsvæði
Starfsfólk
27.048
Leit
Hreinsa leit
Loka leit
Google forrit
Aðalvalmynd